VistaGen Therapeutics was founded
in the late 1990s by a team of scientists believing that better cells lead to
better medicine. In the years since, this California-based clinical-stage
biopharmaceutical company also has focused on developing groundbreaking
medicine for depression and other diseases and conditions involving the central
nervous system.
VistaGen continues to expand the
scope of its pipeline opportunities, employing its world-class biopharma
expertise to gain a unique position that allows it to pursue potentially
valuable research and clinical development collaborations. Last month, VistaGen
revealed that it had signed a valuable Cooperative Research and Development
Agreement, or CRADA, with the U.S. National Institute of Mental Health (NIMH),
a division of the prestigious U.S. National Institutes of Health (NIH). Under
the new agreement, the NIMH and VistaGen will collaborate on a
fully-NIH-sponsored phase 2 efficacy study of AV-101, the company’s
orally-active NMDA receptor modulator for the treatment of major depressive
disorder (MDD).
Like ketamine, an anesthetic
receiving a lot of attention for its potential to treat MDD, AV-101 has a
fundamentally novel mechanism of action compared to all FDA-approved
antidepressants and will be studied in subjects with MDD, a far-reaching and
devastating mental disorder affecting millions of people around the globe.
AV-101 differs from ketamine, however, in that, in VistaGen’s NIH-funded phase
1 clinical studies, it produced no ketamine-like psychotic side effects and it
can be orally administered (ketamine is administered intravenously).
The NIH-sponsored Phase 2
clinical trial will be a crossover study conducted at the NIH and designed to
assess the effectiveness and safety of a single oral dose of AV-101
administered once a day for 14 days to approximately 25 subjects with MDD. The
study will be randomized, double-blind and placebo-controlled, and the primary
measure of effectiveness will be a standard scale for measuring depression
severity, the Hamilton Depression Rating Scale. VistaGen and the NIH expect to
announce the results of the study near the end of 2015.
Dr. Carlos Zarate, Chief of the
Section on the Neurobiology and Treatment of Mood Disorders and Chief of the
Experimental Therapeutics and Pathophysiology Branch at the NIMH, will be the
study’s chief investigator. Dr. Zarate and his team have extensive clinical
experience with ketamine and other NMDA receptor modulators.
The VistaGen team is clearly
excited by the strong preclinical efficacy data supporting the potential
antidepressant effects of AV-101 similar to the results reported in NIH studies
involving ketamine, as well as the efficient oral-delivery and clinical safety
range demonstrated by its successful phase 1 clinical studies. The group looks
forward to collaborating closely with Dr. Zarate’s team to complete this
important AV-101 Phase 2 study in MDD by year end.
Based on preclinical studies,
AV-101 may also serve as a potential treatment for other CNS-related conditions
such as chronic neuropathic pain and epilepsy, as well as neurodegenerative
diseases such as Parkinson’s disease and Huntington’s disease.
For more information, visit
www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment